Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Open-Label Phase II Study in Anti-GBM Disease (Goodpasture's Disease) With Adverse Renal Prognosis to Evaluate the Efficacy and Safety of IdeS - GOOD-IDES

Next Previous
Search
Trial Profile

Open-Label Phase II Study in Anti-GBM Disease (Goodpasture's Disease) With Adverse Renal Prognosis to Evaluate the Efficacy and Safety of IdeS - GOOD-IDES

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 05 Jul 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Imlifidase (Primary)
  • Indications Anti-glomerular basement membrane disease
  • Focus Proof of concept; Therapeutic Use
  • Acronyms GOOD-IDES-01

    • Most Recent Events

    • 29 Jun 2023 Results using imlifidase to elucidate the characteristics and importance of anti-GBM antibodies produced after start of treatment, published in the Nephrology Dialysis Transplantation
    • 24 Sep 2020 According to an Hansa Biopharma AB media release, more information about this trial will be presented at Capital Markets Day planned for October 29, 2020 in Copenhagen.
    • 24 Sep 2020 Results published in Hansa Biopharma AB Media Release

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top